Seeking Novel Drug Candidates and Targets for Progressive Fibrosing Interstitial Lung Diseases and Acute Respiratory Distress Syndrome

CSL is interested in respiratory therapeutics in the areas of Interstitial Lung Diseases (ILD) and Acute Respiratory Distress Syndrome (ARDS).

For ILD-related research, *halting and reversing fibrosis is a key element of interest*. For ARDS-related research, a focus on Community Acquired Pneumonia (CAP) is of key importance.

**Approaches of Particular Interest**

- Biologics and Antibody Therapeutics will be prioritized
- Cell and Gene Therapies

**Developmental Stage**

Validation with patient data, biomarkers, and/or in animal models preferable. Ex vivo models (e.g. human lung tissue) are also of high interest. Multi-omics data approaches welcome.

**Submission Information**

One-page research summaries are encouraged, plus any relevant non-confidential supporting documents

**Out of Scope**

Small molecule approaches are not of interest, with RNA approaches being of low interest

**Opportunity for Collaboration**

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).

**Opportunities sought**

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spin-out companies

**Submissions**

Please submit relevant, non-confidential opportunities online via: [discover.in-part.com](http://discover.in-part.com)

Deadline: 19th October 2020 - 10:59 pm GMT

Have any questions? Contact our team at [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

CSL develops and delivers biotherapies for people with life-threatening medical conditions. CSL's broad range of therapies include those to treat disorders such as haemophilia and primary immune deficiencies.